Faculty ProfilesVivek Jain, MD, MAS
1001 Potrero Ave
San Francisco, CA 94110
Vivek Jain, M.D., M.A.S. is an assistant professor of medicine and infectious diseases in the Division of HIV, Infectious Diseases & Global Medicine at Zuckerberg San Francisco General Hospital at the University of California, San Francisco.
He is an infectious disease specialist focused on HIV, general infectious diseases, and internal medicine. He is the director of the San Francisco General Hospital (SFGH) Infectious Diseases Clinic, Co-Director of the SFGH Infection Control and Prevention Team, attends on the Infectious Disease Consult Service, serves as an HIV-focused primary care doctor in the Positive Health Practice Clinic of SFGH, and is Co-director of the Communicable Diseases course in the UCSF Global Health Sciences Masters' Degree program.
He conducts implementation science research on HIV antiretroviral therapy (ART) delivery in resource limited settings, working with collaborators at Makerere University and the Infectious Diseases Research Collaboration in Kampala, Uganda and in Kenya. The goal of this research is to develop, test and understand the optimal implementation of systems of care for HIV-positive persons in Sub-Saharan Africa. This includes early diagnosis of HIV, immediate/early treatment of HIV with antiretroviral therapy, and improving infectious disease diagnostics for clinics and hospitals. Dr. Jain's research includes the EARLI Study (one of Africa's first studies of ART administration to individuals with high CD4+ T-cell counts), the SEARCH Study (a large cluster randomized trial of wide scale HIV testing and universal HIV ART in 32 communities in Uganda and Kenya), and the RAPID-VL Study (a cluster randomized trial of a novel combination intervention to optimize the way HIV viral load testing is performed in HIV clinics in Uganda).
Dr. Jain earned his undergraduate degree in Biochemistry from Harvard University, followed by his M.D. from Stanford University School of Medicine. He completed residency, chief residency, and infectious diseases fellowship at UCSF, and M.A.S. degree in clinical research also at UCSF.
Education and Training
|Location||Degree or Training||Specialty||Date|
|UCSF||M.A.S.||Epidemiology and Biostatistics||2010|
|UCSF||Chief Residency||Internal Medicine||2007|
|Stanford University School of Medicine||M.D.||2003|
ART delivery, HIV, HIV antiretroviral therapy (ART), HIV drug resistance, HIV immunology, HIV therapeutic strategies, HIV virology, Sub Saharan Africa, acute/early HIV disease, clinical cohorts, clinical trials, early ART, implementation science, infectious disease, resource limited settingsIn the News
- Getting to Zero in San Francisco (Dec 03, 2013)
- Early Treatment May Improve Socioeconomic Conditions for People in Rural Sub-Saharan Africa With HIV (Jul 26, 2012)
- Population Viral Load Decreases in 'Test and Treat' Study in Uganda (Jul 25, 2012)
- SEARCH Study Shows 1-Year Drop in HIV Virus Levels in Rural Ugandan Parish After Community Health Campaign (Jul 24, 2012)
- ART Initiation During Early HIV Infection Associated With Improved Immunologic, Virologic Parameters: Presented at CROI (Mar 04, 2011)
Recent Articles (41)
Kwarisiima, D., Kamya, M.R., Owaraganise, A., Mwangwa, F., Byonanebye, D.M., Ayieko, J., Plenty, A., Black, B., Clark, T.D., Nzarubara, B., Snyman, K., Brown, L., Bukusi, E., Cohen, C.R., Geng, E.H., Charlebois, E.D., Ruel, T.D., Petersen, M.L., Havlir, D., and Jain, V.. High Rates of Viral Suppression in Adults and Children with High CD4+ Counts using a Streamlined ART Delivery Model in the SEARCH Trial in Rural Uganda and Kenya. J Int AIDS Soc. 2017; (In Press.).
Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Mwangwa F, Kadede K, Jain V, Plenty A, Brown L, Lavoy G, Schwab J, Black D, van der Laan M, Bukusi EA, Cohen CR, Clark TD, Charlebois E, Kamya M, Havlir D. Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA. 2017 Jun 06; 317(21):2196-2206.
Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, Deng X, Murphy G, Welte A, Facente SN, Hecht F, Deeks SG, Pillai SK, Busch MP. HIV Antibodies Detect HIV Persistence and Low Level Viral Replication. J Infect Dis. 2017 May 11.
Brown LB, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Black D, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV. Predictors of retention in HIV care among youth (15-24) in a universal test-and-treat setting in rural Kenya. J Acquir Immune Defic Syndr. 2017 Apr 06.
Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, Sang N, Black D, Clark TD, Ladai A, Plenty A, Kabami J, Ssemmondo E, Bukusi EA, Cohen CR, Charlebois ED, Kamya MR, Havlir DV. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2016 Dec 15.
Brown LB, Havlir DV, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED. High levels of retention in care with streamlined care and universal test-and-treat in East Africa. AIDS. 2016 Sep 6.
Ramirez CM, Sinclair E, Epling L, Lee SA, Jain V, Hsue PY, Hatano H, Conn D, Hecht FM, Martin JN, McCune JM, Deeks SG, Hunt PW. Immunologic profiles distinguish aviremic HIV-infected adults. AIDS. 2016 Jun 19; 30(10):1553-62.
Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, Ayieko J, Mwangwa F, Jain V, Byonanebye D, Petersen M, Havlir D, Kamya MR. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016; 11(5):e0156309.
Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, Thirumurthy H, Liegler T, Balzer LB, Petersen ML, Cohen CR, Bukusi EA, Kamya MR, Havlir DV, Charlebois ED. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016 Mar; 3(3):e111-9.
Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda. PLoS One. 2015; 10(12):e0143433.
Baxi SM, Chan D, Jain V. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature. Infection. 2015 Dec; 43(6):751-4.
Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, Chamie G, Clark TD, Rooney JF, Charlebois ED, Kamya MR, Havlir DV. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/µl in rural Uganda. AIDS. 2014 Sep 24; 28(15):2241-9.
Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, Hunt PW, Martin JN, Pilcher CD, Sekaly R, McCune JM, Hecht FM, Deeks SG. Programmed death-1 expression on CD4? and CD8? T cells in treated and untreated HIV disease. AIDS. 2014 Jul 31; 28(12):1749-58.
Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014 May; 10(5):e1004078.
Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014 Mar 1; 65(3):327-32.
Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014 Aug 1; 210(3):374-82.
Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health. 2014 Apr; 19(4):459-68.
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014; 9(1):e84317.
Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013; 13:1151.
Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/µL under routine program conditions in Uganda. Clin Infect Dis. 2013 Nov; 57(9):1343-50.
Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013 Oct 15; 208(8):1202-11.
Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20; 27(4):627-34.
Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb; 56(4):598-605.
Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013 Jul; 208(1):50-6.
Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/µL in a public health setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7.
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7(8):e43400.
Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011 Apr 15; 203(8):1174-81.
Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One. 2010; 5(12):e15510.
Jain V, Yang MH, Kovacicova-Lezcano G, Juhle LS, Bolger AF, Winston LG. Infective endocarditis in an urban medical center: association of individual drugs with valvular involvement. J Infect. 2008 Aug; 57(2):132-8.
Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, Jain V, Cunliffe NA, Nakagomi O, Kirkwood CD, Fischer TK, Parashar UD, Bresee JS, Jiang B, Glass RI. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005 Sep 1; 192 Suppl 1:S146-59.
Clark HF, Lawley DA, Schaffer A, Patacsil JM, Marcello AE, Glass RI, Jain V, Gentsch J. Assessment of the epidemic potential of a new strain of rotavirus associated with the novel G9 serotype which caused an outbreak in the United States for the first time in the 1995-1996 season. J Clin Microbiol. 2004 Apr; 42(4):1434-8.
Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J, Jain V, Bailey K, Karow M, Fandl J, Samuelsson SJ, Ioffe E, Rudge JS, Daly TJ, Radziejewski C, Yancopoulos GD. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol. 2003 Jan; 10(1):38-44.
Jain V, Mekalanos JJ. Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar typhimurium-based DNA vaccine delivery systems. Infect Immun. 2000 Feb; 68(2):986-9.
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996 Dec 27; 87(7):1161-9.